HEARTSCIENCES INC (HSCS)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$3.73+11.01%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · HSCS
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Finalize the proposed business combination with Fortitude Mining Holdings to create a combined company operating under the Fortitude brand and listed on Nasdaq.
Stated as a priority in 3 disclosures including 2026-Q2. The merger agreement was announced in June 2026 with expected closing in H2 2026. Fortitude invested in HeartSciences shares in August 2026 to support the transaction. The trajectory is delivering as the transaction progresses toward closing.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“HeartSciences filed preliminary proxy statement for business combination with Fortitude Mining Holdings; transaction expected to close in H2 2026.”
“Fortitude and HeartSciences entered into definitive merger agreement; transaction expected to close in H2 2026.”
Develop and commercialize the MyoVista Insights platform and MyoVista wavECG device with AI-ECG algorithms and pursue FDA clearance.
Newly stated in 2026-Q2. Management reported the full commercial launch of MyoVista Insights and FDA submission of the MyoVista wavECG device. Financials show no meaningful revenue yet, indicating early-stage commercialization with limited revenue delivery so far.
“Full commercial launch of MyoVista Insights platform and submission of MyoVista wavECG device to FDA for 510(k) clearance.”
Focus on reducing operating losses and improving financial results amid sustained revenue challenges.
Stated in 1 quarter (2026-Q2). Financials show no meaningful revenue for Fiscal 2026 and operating losses increased from -$2.07M in 2026-Q2 to -$2.54M in 2026-Q4. The trajectory shows continued operating losses and stagnant revenue, indicating limited progress on improving financial performance.
“Fiscal 2026 was a year of transformational change; reported no meaningful revenue and operating losses continued.”
Maintain transparent communication and engagement with institutional investors following the merger with Fortitude.
Newly stated in 2026-Q3 (August 2026). Fortitude invested in HeartSciences shares via private placement to support operating expenses pre-merger, reflecting engagement with institutional investors. This is an initial step with limited further data on ongoing transparency or engagement.
Grow Fortitude's Zcash mining operations with expanded power capacity, equipment deployment, and cost reduction initiatives.
Stated in 2 disclosures including 2026-Q2. Fortitude reported mining 33,646 ZEC in Q2 2026 with a power portfolio exceeding 60 MW and plans to reduce mining costs from $70 to $40 per coin. The trajectory shows active growth and operational expansion consistent with management's stated priorities.
“Fortitude's vertically integrated Zcash strategy includes hardware procurement, infrastructure deployment, and power portfolio expansion.”
Over the trailing year it converted 0.98x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, Fed net liquidity, long-term interest rates, real (inflation-adjusted) rates (low R² over the window).
25 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.